Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
NYS Entity Status
NYS Filing Date
MAY 13, 2014
NYS DOS ID#
NYS Entity Type
FOREIGN LIMITED LIABILITY COMPANY
2014 - CHENG & FEISHA, LLC
AROUND THE WEB
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
- Women of Sex Tech, Unite
By ANNA NORTH - Friday Aug 18, 2017
New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.
- Forget the Gym---She'll Stick With Field Hockey
Saturday Sep 2, 2017
After playing the sport in college and internationally, designer Nina Cheng finds the game she loves in the middle of New York City.
- Fit City: Taking Night-Life Cue, Gyms Lower the Lights
By TATIANA BONCOMPAGNI - Tuesday Jun 13, 2017
Cycling, boxing and running studios, as well as some full-service gyms, are using sophisticated lighting systems to heighten the exercise experience.
- Cool Or Cruel? Why Nina Cheng Says It’s Ok To Buy Her Funky Fur Phone Cases
By Elizabeth Segran - Thursday Jul 27, 2017
Fur is not dead: Design startup Wild and Woolly makes a splash with colorful fur accessories—phone cases, bags, and even earrings.
When Gisele Bundchen appeared earlier this month on the cover of Paris Vogue’s faux fur issue, animal activists hailed it as a major victory. After all, more than a decade ago, PETA stage invaders crashed a New York catwalk with signs declaring “Gisele: Fur Scum.” It was 2002 and the anti-fur movement that exploded in the 1990s was still hot. Bundchen, now the highest-paid model in the world, was just 22. Tom Brady’s wife has since become an ally of the group that once protested her and declared on Instagram that wearing real fur “is never an option.”
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]